Merus N.V.'s COO & GC Silverman Peter B. makes significant trades on 2025-07-09 & 2025-07-10.

Merus N.V. (MRUS) has disclosed that Chief Operating Officer and General Counsel, Peter B. Silverman, executed the following transactions on July 9 and 10, 2025. On July 9, Silverman acquired 6695 shares at $18.61 per share and subsequently sold the same number of shares at $55 per share. On the following day, he purchased 16,805 shares at $18.61 per share and sold an identical number of shares at $55 per share.

Merus NV (MRUS), a Netherlands-based biotechnology company focused on developing cancer therapeutics, has seen its stock price rise significantly in recent months. The company's stock has gained 29.9% over the past three months, fueled by encouraging interim results from a phase II study evaluating its bispecific antibody, petosemtamab (MCLA-158), in combination with Merck’s Keytruda (pembrolizumab) [2].

On July 9 and 10, 2025, Chief Operating Officer and General Counsel, Peter B. Silverman, executed a series of transactions involving Merus NV shares. On July 9, Silverman acquired 6695 shares at $18.61 per share and subsequently sold the same number of shares at $55 per share. On the following day, he purchased 16,805 shares at $18.61 per share and sold an identical number of shares at $55 per share [3].

The transactions indicate that Silverman bought a total of 23,550 shares at an average price of $18.61 per share and sold the same number of shares at an average price of $55 per share. This results in a total profit of $1,060,395 from the transactions.

Silverman's transactions come at a time when the company's stock has been performing well, driven by positive clinical trial results and the potential of its cancer therapeutics. However, it is essential to note that such transactions do not necessarily indicate a change in the company's outlook or the potential for future growth.

References:
[1] https://www.marketsmojo.com/stocks-analysis/merus-nv-1137942-210
[2] https://www.nasdaq.com/articles/mrus-stock-soars-30-3-months-after-phase-ii-cancer-study-success
[3] Merus NV's COO Executes Significant Share Transactions